Breaking News To Trading Moves

Meta to acquire Chinese-founded AI startup Manus to boost advanced AI features Meta is buying Manus, a fast-rising “AI agent” startup with roots in China and headquarters in Singapore and the key word here is agent. Not just chat. The market is shifting from “talk to an AI” to “AI does the work,” and Meta wants in. What Happened Meta said it will acquire Manus to accelerate advanced AI features ac...

Ultragenyx Plunges After Setrusumab Miss: When “Better BMD” Doesn’t Mean Fewer Fractures A rare-disease biotech just got cut in half after a Phase 3 miss. Ultragenyx’s setrusumab improved bone density, but didn’t deliver what investors really needed: fewer fractures. What Happened Ultragenyx ($RARE) said its late-stage studies of setrusumab (UX143) in osteogenesis imperfecta (brittle-bone disease)...

SoftBank to buy DigitalBridge ($DBRG) in $4B deal to supercharge AI data center buildout SoftBank agreed to acquire DigitalBridge ($DBRG) in a deal valued at about $4 billion, paying $16 per share (about a 15% premium). DigitalBridge CEO Marc Ganzi stays on to run it as a separately managed platform. The big takeaway: SoftBank is leaning harder into AI infrastructure, and that usually means more s...

Verisk pulls plug on $2.35B AccuLynx deal after FTC review delay INTRO Welcome back to Breaking News to Trading Moves, where we turn market headlines into clear watchlists and trade-ready themes. WHAT HAPPENED Verisk Analytics ($VRSK) terminated its planned roughly $2.35B cash acquisition of AccuLynx, a roofing contractor software provider, after the US Federal Trade Commission did not complete it...

Sable Offshore ($SOC) drops about 13% after environmental groups sue to block the restart of its California Las Flores pipeline. What happened A federal regulator (PHMSA, under the US Department of Transportation) recently approved restarting parts of Sable’s Las Flores pipeline system and said sections fall under federal (not state) oversight. The very next trading day, environmental groups inclu...

China sanctions US defence firms over Taiwan arms sales China just announced sanctions on 20 US defence companies and 10 individuals tied to recent US arms sales to Taiwan. Markets may treat the move as mostly symbolic, but it adds another layer of geopolitical risk that can shift defence, aerospace, China-exposed mega caps, and China ADR sentiment. What happened China said it will freeze any Chin...

Target ($TGT) draws activist pressure as Toms Capital builds stake, FT reports What happened Target is back in the activist spotlight after reports that hedge fund Toms Capital Investment Management (TCIM) has built a significant, undisclosed stake. The timing matters: Target has been fighting weak sales trends and the stock has lagged badly this year. The market’s immediate read is simple — activ...

Coupang ($CPNG) says leaked customer data was deleted, but South Korea says probe still ongoing WHAT HAPPENED Coupang says a former employee downloaded personal info tied to about 3,000 customers and later deleted it without sharing it with any 3rd party. South Korea’s Ministry of Science says the investigation is still ongoing and it has not confirmed Coupang’s deletion claim, and it criticised C...

Honda buys $2.86B Ohio battery-plant assets from LG Energy Solution JV partner What happened LG Energy Solution will sell a factory building and related assets at its Ohio battery joint-venture site to Honda’s US unit for about $2.86B. The deal excludes land and equipment, and LGES said the goal is to improve joint-venture operational efficiency. LGES is exiting the JV, and production is expected...

US FDA approves Omeros drug Yartemlea for TA-TMA (first approved treatment for this dangerous post-transplant complication) Intro Welcome back to Breaking News to Trading Moves, where we turn market-moving headlines into long and short trading ideas. Today’s big biotech headline: the FDA approved Omeros’ Yartemlea for TA-TMA, a serious complication that can occur after stem cell transplants. What...

BP nears deal to sell 65% of Castrol to Stonepeak (valuing Castrol at about $10.1B) What happened BP says it agreed to sell a 65% stake in its Castrol lubricants business to U.S. investment firm Stonepeak for about $6B. BP keeps 35% in a JV and can sell the remainder after a 2-year lock-in. BP also referenced about $800M in accelerated dividend payments tied to the transaction, and the deal is exp...

Sanofi to buy Dynavax for $2.2B: big bet on adult vaccines (hep B + shingles) What happened Sanofi ($SNY) agreed to acquire Dynavax ($DVAX) in an all-cash deal valued at about $2.2B (reported price: $15.50/share). The goal is to strengthen Sanofi’s adult vaccine lineup with Dynavax’s marketed hepatitis B vaccine (Heplisav-B) and an early-stage shingles candidate (Z-1018). Deal is expected to close...

Nvidia–Groq megadeal (reported ~$20B): what it means for AI inference, chips, and data centres What happened On December 24, reports said $NVDA was doing a roughly $20B deal tied to AI chip start-up Groq. The companies’ statements point to a non-exclusive technology licensing agreement plus senior executive hires (including Groq’s founder/CEO Jonathan Ross), while Groq continues operating independ...

ServiceNow ($NOW) to buy Armis for $7.75B (all-cash) to ramp up “cybersecurity for AI” What happened ServiceNow announced its largest-ever acquisition: buying cybersecurity firm Armis for $7.75B in an all-cash deal, aimed at building more proactive security across AI-era infrastructure (cloud, devices, OT/IoT). The deal is expected to close in the 2nd half of 2026 and will be funded with cash and...

DOJ settles with Blackstone’s LivCor in RealPage rent “algorithmic collusion” case What happened The U.S. Department of Justice reached a settlement with LivCor, a Blackstone-owned property management firm, over claims that competing landlords shared non-public rental pricing information via RealPage software to coordinate rent increases. LivCor agreed to stop setting prices based on other landlor...

FDA approves Novo Nordisk’s Wegovy weight-loss pill; $NVO jumps and $LLY faces new oral-GLP-1 competition Reuters reports the FDA approved Novo Nordisk’s Wegovy weight-loss pill, making Novo the first to market with a potent oral obesity drug. Novo shares jumped (including the US-listed ADR), while Eli Lilly traded roughly flat as investors weighed how fast Lilly can catch up with its own oral con...

Huntington ($HBAN) and Cadence ($CADE) get key regulatory green light, merger expected to close February 1, 2026 Welcome to Breaking News to Trading Moves, long and short trading ideas. Today we are covering a major regional bank M and A update: Huntington and Cadence just cleared a big regulatory hurdle, which typically reduces deal risk and can move both the acquirer and target, plus the wider r...

Trian + General Catalyst to buy Janus Henderson for $7.4B What happened Janus Henderson Group $JHG agreed to be acquired in an all-cash deal led by Nelson Peltz’s Trian and General Catalyst at $49 per share, valuing the firm at about $7.4B. The offer is an 18% premium to the “unaffected” close on October 24, 2025, and the deal is expected to close by mid-2026, with CEO Ali Dibadj staying on. Why t...

Alphabet agrees to buy Intersect in $4.75B deal to bolster power for AI data centres Google’s parent $GOOGL is making a power move. Alphabet just agreed to acquire Intersect for $4.75 billion (cash plus assumed debt) to secure more energy and data-centre infrastructure as AI ramps electricity demand. What happened Alphabet announced a definitive agreement to buy Intersect, a firm focused on data-c...

Infosys ADRs spike ~40% on NYSE, trading halts, company says no “material events” Today we’re talking about a weird one: Infosys ADRs on the NYSE ripping almost 40% in minutes, getting halted, and then the company coming out to say: nothing material happened. So what does a move like that mean for traders and which US-listed names could feel the knock-on effects? What happened Infosys ADRs experie...

Clearwater Analytics ($CWAN) to Go Private in $8.4B Deal: Read-through for Fintech SaaS and PE Deal Appetite Clearwater Analytics ($CWAN) agreed to be acquired in an $8.4 billion take-private deal. Let’s break down what happened, why it matters for fintech software valuations, and which US-listed stocks could be the winners and losers from here. WHAT HAPPENED Clearwater Analytics ($CWAN) signed a...

Samsung Biologics buys GSK’s Maryland drug facility for $280M as pharma tariffs loom A major biomanufacturing footprint just moved onto US soil. Samsung Biologics is buying a drug production site in Rockville, Maryland from GSK for $280M, with plans to expand capacity and upgrade technology. The deal is expected to close by end of Q1 2026, and it plugs directly into the bigger theme: companies rac...

Musk wins appeal: Tesla’s 2018 pay package is back on the table Opening Welcome back to Breaking News to Trading Moves — the show that turns market headlines into long and short trading ideas. Today: a major legal win for Elon Musk that clears a big governance overhang for $TSLA. What happened Delaware’s Supreme Court reinstated Elon Musk’s 2018 Tesla compensation plan, reversing a lower-court dec...

UNP–NSC $85B rail mega-merger enters regulatory review What happened Union Pacific ($UNP) and Norfolk Southern ($NSC) have filed a detailed merger application with the U.S. Surface Transportation Board (STB), kicking off the formal regulatory review for their roughly $85B deal. If approved, it would create the first coast-to-coast U.S. freight railroad. Why this matters Speed + reliability vs truc...

Carnival boosts profit outlook, reinstates dividend, and signals strong 2026 demand What happened Carnival ($CCL) beat Q4 earnings expectations, guided full-year adjusted EPS up to $2.48 (above consensus), and reinstated a $0.15 quarterly dividend for the 1st time since the pandemic. Shares jumped as much as 10.2% as the company pointed to strong booking momentum heading into the key “wave season”...